vs
ADMA BIOLOGICS, INC.（ADMA）与COMSCORE, INC.（SCOR）财务数据对比。点击上方公司名可切换其他公司
ADMA BIOLOGICS, INC.的季度营收约是COMSCORE, INC.的1.5倍（$139.2M vs $93.5M），ADMA BIOLOGICS, INC.净利率更高（35.5% vs 3.2%，领先32.2%），ADMA BIOLOGICS, INC.同比增速更快（18.4% vs -1.5%），ADMA BIOLOGICS, INC.自由现金流更多（$34.6M vs $2.9M），过去两年ADMA BIOLOGICS, INC.的营收复合增速更高（30.4% vs 3.8%）
ADMA生物制剂公司是一家专注于研发、生产及商业化特种血浆来源免疫球蛋白疗法的生物制药企业，主要面向美国市场，为原发性免疫缺陷及其他免疫相关疾病患者、医护人员和医疗机构提供免疫健康领域的治疗方案。
Comscore是总部设于美国的全球媒体测量与分析企业，为企业、广告代理商、品牌营销方及媒体出版方提供专业营销数据与分析服务，在全球媒体行业和营销领域拥有广泛影响力。
ADMA vs SCOR — 直观对比
营收规模更大
ADMA
是对方的1.5倍
$93.5M
营收增速更快
ADMA
高出19.9%
-1.5%
净利率更高
ADMA
高出32.2%
3.2%
自由现金流更多
ADMA
多$31.6M
$2.9M
两年增速更快
ADMA
近两年复合增速
3.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $139.2M | $93.5M |
| 净利润 | $49.4M | $3.0M |
| 毛利率 | 63.8% | 41.0% |
| 营业利润率 | 45.1% | 7.0% |
| 净利率 | 35.5% | 3.2% |
| 营收同比 | 18.4% | -1.5% |
| 净利润同比 | -55.9% | -3.7% |
| 每股收益（稀释后） | $0.20 | $9.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ADMASCOR
| Q4 25 | $139.2M | $93.5M | ||
| Q3 25 | $134.2M | $88.9M | ||
| Q2 25 | $122.0M | $89.4M | ||
| Q1 25 | $114.8M | $85.7M | ||
| Q4 24 | $117.5M | $94.9M | ||
| Q3 24 | $119.8M | $88.5M | ||
| Q2 24 | $107.2M | $85.8M | ||
| Q1 24 | $81.9M | $86.8M |
净利润ADMASCOR
| Q4 25 | $49.4M | $3.0M | ||
| Q3 25 | $36.4M | $453.0K | ||
| Q2 25 | $34.2M | $-9.5M | ||
| Q1 25 | $26.9M | $-4.0M | ||
| Q4 24 | $111.9M | $3.1M | ||
| Q3 24 | $35.9M | $-60.6M | ||
| Q2 24 | $32.1M | $-1.7M | ||
| Q1 24 | $17.8M | $-1.1M |
毛利率ADMASCOR
| Q4 25 | 63.8% | 41.0% | ||
| Q3 25 | 56.3% | 40.6% | ||
| Q2 25 | 55.1% | 40.6% | ||
| Q1 25 | 53.2% | 39.6% | ||
| Q4 24 | 53.9% | 42.4% | ||
| Q3 24 | 49.8% | 41.2% | ||
| Q2 24 | 53.6% | 39.5% | ||
| Q1 24 | 47.8% | 42.3% |
营业利润率ADMASCOR
| Q4 25 | 45.1% | 7.0% | ||
| Q3 25 | 38.0% | 1.9% | ||
| Q2 25 | 35.1% | -1.9% | ||
| Q1 25 | 30.4% | -2.4% | ||
| Q4 24 | 32.6% | 4.1% | ||
| Q3 24 | 33.1% | -67.4% | ||
| Q2 24 | 36.6% | -2.2% | ||
| Q1 24 | 26.7% | -2.2% |
净利率ADMASCOR
| Q4 25 | 35.5% | 3.2% | ||
| Q3 25 | 27.1% | 0.5% | ||
| Q2 25 | 28.1% | -10.6% | ||
| Q1 25 | 23.4% | -4.7% | ||
| Q4 24 | 95.2% | 3.3% | ||
| Q3 24 | 30.0% | -68.5% | ||
| Q2 24 | 29.9% | -2.0% | ||
| Q1 24 | 21.7% | -1.2% |
每股收益（稀释后）ADMASCOR
| Q4 25 | $0.20 | $9.50 | ||
| Q3 25 | $0.15 | $-0.86 | ||
| Q2 25 | $0.14 | $-2.73 | ||
| Q1 25 | $0.11 | $-1.66 | ||
| Q4 24 | $0.45 | $-0.47 | ||
| Q3 24 | $0.15 | $-12.79 | ||
| Q2 24 | $0.13 | $-1.19 | ||
| Q1 24 | $0.08 | $-1.08 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $87.6M | $23.6M |
| 总债务越低越好 | $72.1M | $41.5M |
| 股东权益账面价值 | $477.3M | $111.4M |
| 总资产 | $624.2M | $407.7M |
| 负债/权益比越低杠杆越低 | 0.15× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资ADMASCOR
| Q4 25 | $87.6M | $23.6M | ||
| Q3 25 | $61.4M | $26.7M | ||
| Q2 25 | $90.3M | $26.0M | ||
| Q1 25 | $71.6M | $31.0M | ||
| Q4 24 | $103.1M | $29.9M | ||
| Q3 24 | $86.7M | $20.0M | ||
| Q2 24 | $88.2M | $14.7M | ||
| Q1 24 | $45.3M | $18.7M |
总债务ADMASCOR
| Q4 25 | $72.1M | $41.5M | ||
| Q3 25 | $72.4M | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | $72.3M | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ADMASCOR
| Q4 25 | $477.3M | $111.4M | ||
| Q3 25 | $431.2M | $-26.3M | ||
| Q2 25 | $398.3M | $-21.7M | ||
| Q1 25 | $373.4M | $-13.5M | ||
| Q4 24 | $349.0M | $-8.3M | ||
| Q3 24 | $231.9M | $-2.7M | ||
| Q2 24 | $188.3M | $45.8M | ||
| Q1 24 | $153.7M | $51.4M |
总资产ADMASCOR
| Q4 25 | $624.2M | $407.7M | ||
| Q3 25 | $568.7M | $406.9M | ||
| Q2 25 | $558.4M | $415.9M | ||
| Q1 25 | $510.6M | $421.5M | ||
| Q4 24 | $488.7M | $430.2M | ||
| Q3 24 | $390.6M | $412.5M | ||
| Q2 24 | $376.4M | $474.1M | ||
| Q1 24 | $350.9M | $477.7M |
负债/权益比ADMASCOR
| Q4 25 | 0.15× | 0.37× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $35.6M | $3.2M |
| 自由现金流经营现金流 - 资本支出 | $34.6M | $2.9M |
| 自由现金流率自由现金流/营收 | 24.8% | 3.1% |
| 资本支出强度资本支出/营收 | 0.8% | 0.3% |
| 现金转化率经营现金流/净利润 | 0.72× | 1.07× |
| 过去12个月自由现金流最近4个季度 | $27.8M | $21.8M |
8季度趋势，按日历期对齐
经营现金流ADMASCOR
| Q4 25 | $35.6M | $3.2M | ||
| Q3 25 | $13.3M | $9.5M | ||
| Q2 25 | $21.1M | $932.0K | ||
| Q1 25 | $-19.7M | $9.1M | ||
| Q4 24 | $50.2M | $-10.0M | ||
| Q3 24 | $25.0M | $12.5M | ||
| Q2 24 | $45.6M | $8.7M | ||
| Q1 24 | $-2.2M | $6.9M |
自由现金流ADMASCOR
| Q4 25 | $34.6M | $2.9M | ||
| Q3 25 | $-1.1M | $9.4M | ||
| Q2 25 | $18.7M | $787.0K | ||
| Q1 25 | $-24.4M | $8.7M | ||
| Q4 24 | $47.5M | $-10.3M | ||
| Q3 24 | $24.0M | $12.4M | ||
| Q2 24 | $43.6M | $8.5M | ||
| Q1 24 | $-4.6M | $6.6M |
自由现金流率ADMASCOR
| Q4 25 | 24.8% | 3.1% | ||
| Q3 25 | -0.8% | 10.5% | ||
| Q2 25 | 15.3% | 0.9% | ||
| Q1 25 | -21.2% | 10.1% | ||
| Q4 24 | 40.4% | -10.8% | ||
| Q3 24 | 20.0% | 14.0% | ||
| Q2 24 | 40.7% | 10.0% | ||
| Q1 24 | -5.6% | 7.6% |
资本支出强度ADMASCOR
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 10.7% | 0.1% | ||
| Q2 25 | 2.0% | 0.2% | ||
| Q1 25 | 4.1% | 0.4% | ||
| Q4 24 | 2.3% | 0.2% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.2% | ||
| Q1 24 | 2.9% | 0.3% |
现金转化率ADMASCOR
| Q4 25 | 0.72× | 1.07× | ||
| Q3 25 | 0.36× | 20.96× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | -3.19× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
